Latest news
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 12:01:01 GMTImmuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:43:03 GMTImmuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 11:43:00 GMT